Insight, China's Pharmaceutical Industry

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

China’s National Healthcare Security Administration (NHSA) released its comprehensive “Five-Year Action Plan for Medical Insurance...

Company Drug

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Fineline Cube May 14, 2026

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential

Fineline Cube May 14, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China’s...

Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...

Company Drug

Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors

Fineline Cube May 14, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...

Company Drug

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Fineline Cube May 13, 2026

Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two...

Company

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Fineline Cube May 13, 2026

Legend Biotech Corporation (NASDAQ: LEGN) reported first-quarter 2026 revenue of USD 305 million, representing 56%...

Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026

Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...

Others

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Fineline Cube May 13, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...

Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...

Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026

Cellular Intelligence announced on May 11, 2026, that it has acquired global rights to Novo...

Others

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Fineline Cube May 13, 2026

Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...

Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026

Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has...

Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced it has received clinical approval from China’s...

Others

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Fineline Cube May 13, 2026

Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026

Boehringer Ingelheim (“BI”) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement...

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Fineline Cube May 13, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced on May 12, 2026, that it has received...

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026

Alphamab Oncology (HKG: 9966) announced the initiation of a Phase II clinical study for its...

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026

Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has...

Insight, China's Pharmaceutical Industry

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem

Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu

Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials

Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

You Missed

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy